Context Therapeutics amended its September 2024 exclusive license agreement with BioAtla for CT-202, a Nectin-4 x CD3 T cell engager bispecific antibody. Context bought out all future milestone and royalty obligations for a $4.5 million upfront payment plus a final $2.0 million payment due by August 1, 2026, in exchange for a fully paid-up, non-terminable license.
Key facts
AnnouncedMay 18, 2026
ClosedMay 18, 2026
Deal value$6M
Deal typeLicensing/Option
Therapeutic areasolid tumors (bladder, colorectal, lung, breast — Nectin-4 expressing)
Indicationssolid tumors (bladder, colorectal, lung, breast — Nectin-4 expressing)
Key assetsCT-202
MechanismNectin-4 x CD3 pH-dependent T cell engager bispecific antibody